{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-020713","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.143034+00:00","generated_at":"2026-05-20T05:52:10.546975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant Q4 net loss widens to $206.5M; brepocitinib DM readout on track for H2 2025","bullets":["Net loss attributable to Roivant of $206.5M ($0.29 loss per share) for Q4 FY2025, vs $151.1M loss ($0.19) a year ago.","Revenue of $7.6M, down 16% YoY; R&D expenses rose 35% to $145.2M.","Consolidated cash, equivalents, restricted cash and marketable securities of $4.9B at March 31, 2025.","Repurchased $1.3B of shares, reducing outstanding shares by 14% from March 31, 2024.","Brepocitinib Phase 3 in dermatomyositis fully enrolled; topline data expected H2 2025; NIU Phase 3 enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-020713","json":"https://secwatch.observer/filing/0001140361-25-020713.json","markdown":"https://secwatch.observer/filing/0001140361-25-020713.md","text":"https://secwatch.observer/filing/0001140361-25-020713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125020713/0001140361-25-020713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125020713/ef20049462_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T05:52:10.546975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}